β-lactamase-mediated resistance: a biochemical, epidemiological and genetic overview
- PMID: 22894615
β-lactamase-mediated resistance: a biochemical, epidemiological and genetic overview
Abstract
Early after the introduction of the first (narrow spectrum) penicillins into clinical use, penicillinase-producing staphylococci replaced (worldwide) the previously susceptible microorganisms. Similarly, the extensive use of broad-spectrum, orally administered β- lactams (like ampicillin, amoxicillin or cefalexin) provided a favorable scenario for the selection of gram-negative microorganisms producing broad spectrum β-lactamases almost 45 years ago. These microorganisms could be controlled by the introduction of the so called "extended spectrum cephalosporins". However, overuse of these drugs resulted, after a few years, in the emergence of extended-spectrum β-lactamases (ESBLs) through point mutations in the existing broad-spectrum β-lactamases, such as TEM and SHV enzymes. Overuse of extended-spectrum β-lactams also gave rise to chromosomal mutations in regulatory genes which resulted in the overproduction of chromosomal AmpC genes, and, in other regions of the world, in the explosive emergence of other ESBL families, like the CTX-Ms. Carbapenems remained active on microorganisms harboring these extended-spectrum β-lactamases, while both carbapenems and fourth generation cephalosporins remained active towards those with derepressed (or the more recent plasmidic) AmpCs. However, microorganisms countered this assault by the emergence of the so called carbapenemases (both serine- and metallo- enzymes) which, in some cases, are actually capable of hydrolyzing almost all β-lactams including the carbapenems. Although all these enzyme families (some of them represented by hundreds of members) are for sure pre-dating the antibiotic era in environmental and clinically significant microorganisms, it was the misuse of these antibiotics that drove their evolution. This paper describes in detail each major class of β-lactamase including epidemiology, genetic, and biochemical evaluations.
Similar articles
-
[Clinically important beta-lactamases of gram-negative bacteria: extended-spectrum beta-lactamases (ESBL)].Epidemiol Mikrobiol Imunol. 2007 Aug;56(3):103-11. Epidemiol Mikrobiol Imunol. 2007. PMID: 17900058 Review. Czech.
-
[Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics].Acta Med Croatica. 2004;58(4):307-12. Acta Med Croatica. 2004. PMID: 15700687 Croatian.
-
Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens.Int J Med Microbiol. 2010 Aug;300(6):371-9. doi: 10.1016/j.ijmm.2010.04.005. Epub 2010 May 27. Int J Med Microbiol. 2010. PMID: 20537585 Review.
-
Defining an extended-spectrum beta-lactamase.Clin Microbiol Infect. 2008 Jan;14 Suppl 1:3-10. doi: 10.1111/j.1469-0691.2007.01857.x. Clin Microbiol Infect. 2008. PMID: 18154524 Review.
-
Characteristics, epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-spectrum beta-lactamases.Res Microbiol. 2004 Jul-Aug;155(6):409-21. doi: 10.1016/j.resmic.2004.02.009. Res Microbiol. 2004. PMID: 15249058 Review.
Cited by
-
Redefining the Origin and Evolution of Chromosomally Encoded blaCTX-M/KLU in the Context of a Revised Taxonomy of Genus Kluyvera.Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0242420. doi: 10.1128/AAC.02424-20. Epub 2021 Jun 17. Antimicrob Agents Chemother. 2021. PMID: 33903106 Free PMC article.
-
Crystal structure of the class A extended-spectrum β-lactamase CTX-M-96 in complex with relebactam at 1.03 Angstrom resolution.Antimicrob Agents Chemother. 2024 Aug 7;68(8):e0172123. doi: 10.1128/aac.01721-23. Epub 2024 Jul 11. Antimicrob Agents Chemother. 2024. PMID: 38990013 Free PMC article.
-
Envelope Structures of Gram-Positive Bacteria.Curr Top Microbiol Immunol. 2017;404:1-44. doi: 10.1007/82_2015_5021. Curr Top Microbiol Immunol. 2017. PMID: 26919863 Free PMC article. Review.
-
Editorial: Structural and Biochemical Aspects of the Interaction of β-Lactamases With State-of-the-Art Inhibitors.Front Microbiol. 2022 Feb 2;13:849324. doi: 10.3389/fmicb.2022.849324. eCollection 2022. Front Microbiol. 2022. PMID: 35185858 Free PMC article. No abstract available.
-
Complete Sequence of the IncA/C1 Plasmid pCf587 Carrying blaPER-2 from Citrobacter freundii.Antimicrob Agents Chemother. 2018 Apr 26;62(5):e00006-18. doi: 10.1128/AAC.00006-18. Print 2018 May. Antimicrob Agents Chemother. 2018. PMID: 29463531 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical